[1] 周迪, 杨勇, 汤朝晖, 等. 肝门部胆管癌日本诊治体系的历史沿革、现状和瓶颈. 中华外科杂志, 2019, 57(1):6-9.
[2] Nagino M. Surgical treatment of perihilar cholangiocarcinoma: resection or transplant?Ann Surg, 2018, 267(5):806-807.
[3] 唐明尧, 陈勇. 肝门部胆管癌临床治疗的研究进展. 中华肝胆外科杂志, 2017, 23(12):857-860.
[4] Li B, Xiong XZ, Zhou Y, et al. Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma. World J Gastroenterol, 2017, 23(36):6685-6693.
[5] 张隽, 乔岐禄, 吴问汉, 等. 术前经皮经肝胆道穿刺引流及门静脉栓塞联合扩大肝切除术治疗局部进展期肝门部胆管癌. 中华肝胆外科杂志, 2017, 23(3):173-175.
[6] 王要轩, 李珂, 田玉伟, 等. 联合肝脏离断和门静脉结扎的二步肝切除技术并肝动脉重建治疗肝门部胆管癌. 中华肝胆外科杂志, 2018, 24(9):600-603.
[7] 中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013版). 中华外科杂志, 2013, 51(10):865-871.
[8] Yoshida K, Matsuyama R, Mori R , et al. Immunohistochemical comparison of malignancy between radial invasion and mucosal extension in hilar cholangiocarcinoma. Anticancer Res, 2017, 37(10):5805-5812.
[9] Zhang TJ, Xue D, Zhang CD, et al. Cullin 4a is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma.World J Gastroenterol, 2017, 23(13):2318-2329.
[10] Wiggers JK , Koerkamp BG , Cieslak KP , et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg, 2016, 18(2):321-331.e41.
[11] Forsmark CE, Diniz AL, Zhu AX. Consensus conference on hilar cholangiocarcinoma. HPB(Oxford), 2015, 17(8):666-668.
[12] Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surg Today, 2017, 47(2):182-192.
[13] VugtJV, Gaspersz M, Coelen R , et al. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. HPB(Oxford), 2018, 20(1):83-92.
[14] 戴海粟, 别平, 王曙光, 等. 联合肝动脉切除重建在肝门部胆管癌根治术中的临床研究. 中华外科杂志, 2018, 56(1):41-46.
[15] Mantel HTJ, Wiggers JK, Verheij J, et al. Lymph node micrometastases are associated with worse survival in patients with otherwise node-negative hilar cholangiocarcinoma. Ann Surg Oncol, 2015, 22(S3):1107-1115.
[16] Peng C, Li C, Wen T, et al. Left hepatectomy combined with hepatic arteryresection for hilar cholangiocarcinoma. Int J Surg, 2016, 32(1):167-173.
[17] Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement. HPB(Oxford), 2015, 17(8):691-699.
[18] Hoffmann K, Luible S, Goeppert B, et al. Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma. Surgery, 2015, 158(5):1252-1260.
[19] Noji T, Tsuchikawa T, Okamura K, et al. Resection and reconstruction of the hepatic artery for advanced perihilar cholangiocarcinoma: result of arterioportal shunting. J Gastrointest Surg, 2015, 19(4):675-681.
[20] Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: Controversies on the extent of surgical resection aiming at cure.Int J Colorectal Dis, 2015, 30(2):159-171. |